Related Experiment Video
Updated: Mar 6, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
12.5K
Chenodeoxycholic Acid Derivative HS-1200 Inhibits Hepatocarcinogenesis and Improves Liver Function in
Miao Xu1, Qi Zhao2, Donghui Shao3
1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China; Department of Gastroenterology, Jinan Hospital, Jinan, Shandong 250013, China.
Biomed Research International
|March 7, 2017
Summary
HS-1200 treatment significantly inhibited liver tumorigenesis and improved liver function in a rat model of hepatocellular carcinoma (HCC). This effect may be linked to the downregulation of the mutT homologue gene 1 (MTH1).
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge.
- Diethylnitrosamine (DEN) is a known carcinogen used to induce HCC in experimental models.
- Understanding the molecular mechanisms underlying hepatocarcinogenesis is crucial for developing effective therapies.
Purpose of the Study:
- To evaluate the efficacy of HS-1200 in preventing liver tumorigenesis.
- To assess the impact of HS-1200 on liver function in an HCC rat model.
- To investigate the role of mutT homologue gene 1 (MTH1) in HS-1200's therapeutic effects.
Main Methods:
- A diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) rat model was established.
- Rats were administered HS-1200 orally at varying doses.
- Key parameters assessed included body weight, liver weight, liver pathology, serum biomarkers (AST, ALT, AFP), and MTH1 mRNA expression.
Main Results:
- HS-1200 administration significantly improved body weight and reduced liver weight and liver coefficient in HCC rats.
- HS-1200 suppressed tumor formation, attenuated liver tissue damage, and lowered serum levels of AST, ALT, and AFP.
- MTH1 mRNA levels, elevated in HCC, were dose-dependently downregulated by HS-1200 treatment.
Conclusions:
- HS-1200 demonstrates significant hepatoprotective and anti-tumorigenic effects in a DEN-induced HCC rat model.
- The compound appears to improve liver function and inhibit cancer progression.
- Downregulation of MTH1 may be a key mechanism through which HS-1200 exerts its beneficial effects on liver health and cancer prevention.
